Kiora Pharmaceuticals posted a Q2 net loss of USD 2.08 million, narrowing from USD 2.15 million a year earlier; loss per share improved to USD 0.34 from USD 0.54.
R&D expense fell to USD 2.08 million from USD 2.59 million; collaboration credits declined to USD 1.34 million from USD 1.69 million.
Cash position, financing and pipeline updates
Cash and short-term investments rose to about USD 16.8 million at June 30 from USD 13.9 million at March 31, extending expected runway into late 2028.
Private placement secured for up to USD 24 million in gross proceeds, including USD 5 million upfront; remaining proceeds tied to milestone-based warrant exercises.
ABACUS-2 advanced into a 100 µg dose cohort with topline data expected in Q3 2027; KLARITY higher-dose enrollment continues with initial data expected late 2026.
KPRX•
